triple glp 1 ​"Triple-Hormone" Drug Shows Record Weight Loss: At the American Diabetes Association's 2026 Scientific Sessions, researchers unveiled phase 3 trial results for retatrutide, the first therapy to Dual GLP-1 / GIP Receptor

With Ivm Healths membership, youll receive personalized healthcare tailored to your individual goals

Thus, the clinical benefits for the risk of heart failure and kidney outcomes, except albuminuria, are likely to be a strength of SGLT2is, whereas those for the risk of stroke are a strength of GLP-1RAs (Graphical Abstract)

Favorece el control del peso cuando se combina con una dieta equilibrada y un estilo de vida activo

Whether continued GCGR-mediated energy expenditure explains the sustained trajectory is not yet formally characterised, but the mechanistic hypothesis is consistent with the animal data

DAPA-CKD Trial Committees and Investigators